MX 1520
Alternative Names: NOX 1520Latest Information Update: 16 Jul 2016
At a glance
- Originator Medinox
- Class Antianaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Sickle cell anaemia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Sickle-cell-anaemia in USA (PO)
- 04 Oct 2004 Preclinical data have been added to the pharmacokinetics and Haematological Disorders pharmacodynamics sections
- 02 Dec 2002 Preclinical data have been added to the adverse events, the pharmacokinetics and Haematological Disorders pharmacodynamics sections